Adlbrecht, C. and Wild, C. (2010): Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors. Decision Support Document 40.

Adlbrecht, C. and Wild, C. (2007): [Targeted radionuclide therapy with 90Y- and 177-Lu-DOTATOC in patients with neuroendocrine tumors. HTA in hospitals]. Decision Support Document 02.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Pieber, T. R. (2002): [Disease management for diabetes mellitus. Editorial]. HTA-Newsletter 5: p. 1.

Siebenhofer-Kroitzsch, A. (2006): [Insulin analogues: Price and treatment strategy. Editorial]. HTA-Newsletter 52: p. 1.

Ujeyl, M. (2012): Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin. DSD: Horizon Scanning in Oncology 24.

Wild, C. (2005): [Insulin pump. Intensive therapy for type 1 diabetes]. HTA-Newsletter 36: p. 4.

Wild, C. (2004): [Short acting insulin analogues in the treatment of diabetes mellitus]. HTA-Newsletter 29: p. 2.

Wild, C. (2002): [Glitazone in the treatment of type 2 diabetes mellitus]. HTA-Newsletter 05: p. 2.

Wild, C. (2002): [Diabetic foot syndrome: Early diagnosis and treatment costs]. HTA-Newsletter 05: pp. 3-4.

Wild, C. (2002): [Insulin analogues]. HTA-Newsletter 05: p. 3.

Wild, C. (2002): [Alpha lipoic acid in the treatment of neuropathy]. HTA-Newsletter 05: pp. 2-3.

Wild, C. and Adlbrecht, C. (2007): [Radiopharmaceuticals in palliative care]. HTA-Newsletter 58: pp. 2-3.

Wild, C. and Mathis, S. and Guba, B. and Gartlehner, G. (2008): [Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review]. Decision Support Document 12.